Men's Health

Is inflammation a potential target for the treatment of BPH? New research being presented at the 2014 AUA annual meeting may help answer this question.

Research in stone disease and minimally invasive surgery will also make its mark at the Society for Pediatric Urology annual meeting, which runs concurrently with the first 3 days of the AUA meeting.

Our traditional thinking about sex steroids is being challenged.

The safety of testosterone replacement therapy has been the subject of two recently published studies, which were followed by a January 2014 FDA announcement that the agency is investigating the risk of stroke, heart attack, and death in men taking TRT. Additional data on the safety of TRT, including its use in men following radical prostatectomy, will be presented at the AUA meeting, said John J. Mulcahy, MD, PhD.

Research in advanced prostate cancer is largely focused on newer agents for metastatic castration-resistant prostate cancer, including abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), radium Ra 223 dichloride (Xofigo), and the immunotherapy sipuleucel-T (Provenge).

A number of studies at the 2014 AUA annual meeting will indicate that male infertility is a harbinger of other diseases, specifically suggesting “linkage to all-cause mortality, psychiatric disorders, morbidity, and offspring birth defect risk,” said James M. Hotaling, MD, assistant professor of surgery in the division of urology at the University of Utah, Salt Lake City.

Drugs and devices in the pipeline from Astellas Pharma, Medivation, Repros Therapeutics, Metamark Genetics, Argos Therapeutics, S1 Biopharma, Ipsen, Sprout Pharmaceuticals, Antigen Express, Generex Biotechnology, Veloxis Pharmaceuticals, and Absorption Pharmaceuticals.

New products and services from Accuray, Cook Medical, OPKO Health, Intuitive Surgical, Skipta, Mauna Kea Technologies, and the National Comprehensive Cancer Network.

This list of U.S.-based National Institutes of Health trials is derived from the NIH’s database and includes phase I-IV hypogonadism and BPH trials that are currently recruiting participants.

About one-fourth of men with slow-growing prostate cancer who undergo active surveillance drop out of the program, according to findings from a relatively small European study.

The American Society of Cataract and Refractive Surgery and the American Academy of Ophthalmology have jointly issued an educational update about cataract surgery complications associated with systemic alpha-blockers based on the recent publication of two studies.

Adding local radiotherapy to hormonal treatment more than halves long-term prostate cancer-specific mortality and substantially decreases overall mortality in men with non-metastatic locally advanced or high-risk prostate cancer, according to an updated analysis of clinical trial data from the Scandinavian Prostate Cancer Group’s Study VII.

Three-dimensional mapping biopsy (3DMB) of the prostate provides a more accurate disease assessment and in doing so may allow more confident decision making when patients and their physicians are trying to resolve issues surrounding observation or more aggressive therapies, a study from the University of Colorado School of Medicine, Denver, suggests.

Higher PSA density at diagnosis is associated with biopsy progression of low-risk prostate cancer in patients enrolled in active surveillance.

Dose-escalated intensity-modulated radiation therapy (IMRT) with use of a moderate hypofractionation regimen (72 Gy in 2.4-Gy fractions) can safely treat patients with localized prostate cancer with limited grade 2 or 3 late toxicity, according to a recently published study.

Among men undergoing radiation therapy for prostate cancer, daily use of the phosphodiesterase type-5 inhibitor tadalafil (Cialis), compared with placebo, did not prevent loss of erectile function, a recently published study found.

This guide features products and services from manufacturers that are exhibiting at the AUA annual meeting in Orlando. Exhibit hall booth numbers have been included so that you can search for product demonstrations and exhibits that are of particular interest to you.

Three professional medical societies and an international group of 130 scientists and physicians have petitioned JAMA to retract a recent article that reported an association between the use of testosterone therapy and increased risk of death, heart attack, or ischemic stroke.

Cholesterol-lowering statin drugs are associated with a significant improvement in erectile function, cardiologists reported in a new meta-analysis.

Laser photoselective vaporization prostatectomy is permitting surgical intervention for BPH in a widening array of patients, many of whom harbor comorbidities that would ordinarily exclude them from invasive procedures, according to a new multinational report.

Primary androgen deprivation therapy in men with localized prostate cancer appears to offer no survival benefit.

The investigational 17,20 lyase inhibitor orteronel failed to significantly extend overall survival in an international phase III study of patients with metastatic castration-resistant prostate cancer.

Although the activity of enzalutamide (XTANDI) is blunted in patients with metastatic castration-resistant prostate cancer who have been treated previously with abiraterone acetate (ZYTIGA), a meaningful number of these patients still experience a decline in PSA level with enzalutamide, according to a recent study.

Testosterone replacement therapy (TRT) in hypogonadal men does not appear to increase the risk for prostate cancer, according to an evaluation of 224 men with an indication for prostate biopsy, providing further evidence that TRT need not be avoided in this patient group.

A study from the UCLA Ronald Reagan Medical Center appears to once again prove that time is money. The study’s findings indicate that up to $15 million could be saved annually by referring patients who are candidates for robot-assisted radical prostatectomy to surgeons and surgical centers with optimal operating times.